Literature DB >> 24813209

A clinically useful self-report measure of the DSM-5 anxious distress specifier for major depressive disorder.

Mark Zimmerman1, Iwona Chelminski, Diane Young, Kristy Dalrymple, Emily Walsh, Lia Rosenstein.   

Abstract

OBJECTIVE: To acknowledge the clinical significance of anxiety in depressed patients, DSM-5 included criteria for an anxious distress specifier for major depressive disorder. In the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, we modified our previously published depression scale to include a subscale assessing the DSM-5 anxious distress specifier.
METHOD: From December 1995 to August 2013, 773 psychiatric outpatients with major depressive disorder completed the Clinically Useful Depression Outcome Scale (CUDOS) supplemented with questions for the DSM-5 anxious distress specifier (CUDOS-A). To examine discriminant and convergent validity, the patients were rated on clinician severity indices of depression, anxiety, and irritability. Discriminant and convergent validity was further examined in a subset of patients who completed other self-report symptom severity scales. Test-retest reliability was examined in a subset who completed the CUDOS-A twice. We compared patients who did and did not meet the DSM-5 anxious distress specifier on indices of psychosocial functioning and quality of life.
RESULTS: The CUDOS-A subscale had high internal consistency and test-retest reliability; was more highly correlated with other self-report measures of anxiety than with measures of depression, substance use problems, eating disorders, and anger; and was more highly correlated with clinician severity ratings of anxiety than depression and irritability. CUDOS-A scores were significantly higher in depressed outpatients with a current anxiety disorder than in depressed patients without a comorbid anxiety disorder (P < .001). Finally, patients who met the DSM-5 anxious distress specifier reported poorer psychosocial functioning and quality of life than patients who did not meet the anxious distress specifier.
CONCLUSIONS: In the present study of a large sample of psychiatric outpatients, the CUDOS-A was a reliable and valid measure of the DSM-5 anxious distress specifier for major depressive disorder. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24813209     DOI: 10.4088/JCP.13m08961

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

Review 1.  Comorbid Anxiety and Depressive Symptoms in Children and Adolescents: A Systematic Review and Analysis.

Authors:  Tabatha H Melton; Paul E Croarkin; Jeffrey R Strawn; Shawn M McClintock
Journal:  J Psychiatr Pract       Date:  2016-03       Impact factor: 1.325

2.  A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.

Authors:  Dawn F Ionescu; David A Luckenbaugh; Mark J Niciu; Erica M Richards; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2014-11-14       Impact factor: 6.744

3.  Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review.

Authors:  Brittany Litster; Kirsten M Fiest; Scott B Patten; John D Fisk; John R Walker; Lesley A Graff; James M Bolton; Jitender Sareen; James J Marriott; Lindsay I Berrigan; Charles N Bernstein; Ryan Zarychanski; Alexander Singer; Carol A Hitchon; Christine A Peschken; Ruth Ann Marrie
Journal:  Int J MS Care       Date:  2016 Nov-Dec

4.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

5.  Anxious-depression among Hispanic/Latinos from different backgrounds: results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Álvaro Camacho; Patricia Gonzalez; Christina Buelna; Kristen T Emory; Gregory A Talavera; Sheila F Castañeda; Rebeca A Espinoza; Annie G Howard; Krista M Perreira; Carmen R Isasi; Martha L Daviglus; Scott C Roesch
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-09-12       Impact factor: 4.328

6.  Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study.

Authors:  Roger S McIntyre; Emmanuelle Weiller
Journal:  Adv Ther       Date:  2015-05-13       Impact factor: 3.845

7.  Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment.

Authors:  Zhiguo Wu; Yiru Fang
Journal:  Shanghai Arch Psychiatry       Date:  2014-08

8.  Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.

Authors:  Lori L Davis; Ai Ota; Pamela Perry; Kana Tsuneyoshi; Emmanuelle Weiller; Ross A Baker
Journal:  Brain Behav       Date:  2016-07-24       Impact factor: 2.708

9.  Mapping the Presence of Anxiety Symptoms in Adults With Major Depressive Disorder.

Authors:  Fenfen Ge; Jingwen Jiang; Yue Wang; Mentong Wan; Wei Zhang
Journal:  Front Psychiatry       Date:  2021-05-19       Impact factor: 4.157

10.  Anxious distress in depressed outpatients: Prevalence, comorbidity, and incremental validity.

Authors:  Anthony J Rosellini; Michelle L Bourgeois; Jeannette Correa; Esther S Tung; Svetlana Goncharenko; Timothy A Brown
Journal:  J Psychiatr Res       Date:  2018-05-08       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.